Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial
Authors
Discussion
Loading...
Member takes
Implication
Observational analysis finds similar vaccine effectiveness on respiratory and cardiovascular outcomes in seniors with or without ASCVD.
Key Points
- Vaccine effectiveness against respiratory outcomes was 80% in individuals without ASCVD, indicating high efficacy.
- Individuals with ASCVD showed no significant vaccine effectiveness for major cardiovascular events, estimated at 12% with overlapping confidence intervals.
- The analysis utilized data from the DAN-RSV trial and assessed heterogeneity in vaccine responses between groups based on ASCVD status.
- Results suggest that the RSVpreF vaccine's effectiveness is comparable regardless of pre-existing cardiovascular conditions.
Cite This Study
Pareek et al. (2025) studied this question.